ESMO 2026 INTELLIGENCE · MADRIDKnow what top breast cancer KOLs think about your drug — before, during and after ESMO. Six seats only.Request the brochure →
GRG Health Talk to our team
INDEPENDENT CONGRESS INTELLIGENCE · BREAST CANCER (HR+/HER2− mBC) · ESMO 2026 · MADRID · 23–27 OCT

Know what the world's top breast cancer doctors think about your drug — before, during, and after ESMO.

Everyone will tell you what happened at ESMO. Only we can tell you what it changed — we have been recording what top doctors believe, drug by drug, all through 2026. After 27 October, that "before" picture can never be made again.

Request the brochure →
77+
DOCTORS ON RECORD
1,400+
DRUG OPINION SCORES
45
DRUGS TRACKED
760+
DOCTOR SURVEY ANSWERS

BEFORE — already on record.

77+ top doctors across 10 countries, recorded all year. 1,400+ opinion scores across 45 drugs. 290+ tagged insights for Medical, Commercial and Market Access teams. 760+ survey answers from practicing cancer doctors. No drug company in the room. Nobody else in the world has this.

DURING — live from Madrid.

A short report in your inbox every morning by 8 AM: what was presented yesterday, marked helps you / hurts you / ignore. Our own doctors walking the halls for you. Overnight polls of doctors on the day's biggest news.

AFTER — proven, not guessed.

Within a week: what actually changed for your drug. Then in December, we ask the doctors again — and show you exactly which opinions moved, and by how much.

Made for your drug. Written for your team.

Every report covers the whole field — but every insight answers one question: what does this mean for YOUR drug? Your trials, your rivals, the five hard questions your people will be asked in Madrid — answered. Written for how your team works: Medical Affairs, Commercial, or Market Access.

  1. 1

    Pre-Congress Brief — ~6 October. Everything at ESMO that touches your drug, where your team should be, and what doctors already think — seen through your drug's lens.

  2. 2

    Big-Results Update — within 48 hours of the late-breaking titles going public. The Phase III results named, plus top doctors reacting to the real list before Madrid.

  3. 3

    Daily Trackers — 24–28 October, by 8 AM. Helps you / hurts you / ignore.

  4. 4

    The Verdict — by 3 November. What actually changed for your drug — every claim checked against FDA and EMA records.

  5. 5

    The Proof — December, included. Doctors surveyed again: which opinions moved, and by how much.

Six seats. One drug per seat. Allocated in order of signature. Pricing and add-ons are in the brochure.

Request the brochure

We send the full brochure the same day and call you within one business day.

Your contact: Tanvi Bahl
Director, Global Oncology Leadership Forum by GRG Health
tanvi.bahl@grgonline.com

Recorded, not remembered. Independently run doctor sessions all year — no drug company in the room.

Checked scans. The ESMO programme searched word by word; even zero results are logged so anyone can verify.

Facts verified. Every approval claim checked against official FDA / EMA records before it reaches you.

Signed by humans. An analyst checks and a senior approves every page you receive.

GOLF — the Global Oncology Leadership Forum — is a live intelligence platform where the world's leading cancer doctors speak openly, on record, with no drug company in the room. Their discussions, debates and survey answers are turned into structured intelligence within days — tracked drug by drug, month by month, all year. That always-on record is what makes this ESMO programme possible: we don't start watching when the congress starts; we've been listening all along. oncogolf.live

GOLF is built by GRG Health — a global healthcare intelligence company working with pharmaceutical companies since 2015, with teams across the US, Europe, India and Asia-Pacific, and a verified network of 500,000+ healthcare professionals worldwide. GRG has spent a decade answering pharma's hardest questions through doctors; GOLF is that experience, made continuous.

An independent research programme by GRG Health — not affiliated with, sponsored or endorsed by ESMO. For research purposes only · Not for promotional use · Run under EFPIA & PhRMA principles · Doctor statements recorded with consent · © GRG Health 2026